Naif Abdullah Al-Dhabi,Savarimuthu Ignacimuthu,P. Pandikumar,Erenius Toppo,Sylvester Darvin
申请号：
US15864704
公开号：
US10064841B1
申请日:
2018.01.08
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Isoandrographolide-19-propionate for treatment of non-alcoholic fatty liver disease (NALFD) relates to the compound isoandrographolide-19-propionate (IAN-19P), having the structural formula:and pharmaceutically acceptable salts thereof. The compound is synthesized by reaction of isoandrographolide with anhydrous propionic acid in the presence of N,N′-dicyclohexylcarbodiimide and 4-dimethylaminopyridine. In vitro testing shows that isoandrographolide-19-propionate has lower toxicity than andrographolide, but has significantly high activity at a concentration of 50 μM. IAN-19P produced normal triglyceride levels and significantly lowered lipoperoxide formation in palmitate-oleate induced steatotic HepG2 cells, and also lowered ALT leakage from the treated cells.
